Not yet recruiting
Non-small cell lung cancer
Not yet recruitingA study comparing 68Ga-FAPI-46 PET scan with standard 18F-FDG PET scan and brain MRI for staging in patients with newly diagnosed non-small cell lung cancer
Registered drugNo placebo
A study comparing 68Ga-FAPI-46 PET scan with standard 18F-FDG PET scan and brain MRI for staging in patients with newly diagnosed non-small cell lung cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)TriacetateFludeoxyglucose (18F)
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
